Kazuaki Maruyama
Has grant
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Elucidation of the pathogenesis of head and neck vascular malformations and hemangioma based on developmental analysis
Open Date: 2023-04-01
Close Date: 2025-03-31
Grant: Close
Defining the differential role of blood and lymphatic vessels in immune modulation and tumor metastasis.
Open Date: 2022-04-01
Close Date: 2023-03-31
Grant: Close
Grant-in-Aid for Young Scientists
Open Date: 2020-04-01
Close Date: 2022-03-01
Grant: Close
Role of neural crest cells in bicuspic aortic valve
Open Date: 2013-04-01
Close Date: 2016-03-31
Articles (18)
Year:
2026
Year:
2026
Congenital vascular malformations, affecting 0.5% of the population, often occur in the head and neck, complicating treatment due to the critical functions in these regions. Our previous research identified distinct developmental origins for blood and lymphatic vessels in these areas, tracing them to the cardiopharyngeal mesoderm (CPM), which contributes to the development of the head, neck, and cardiovascular system in both mouse and human embryos. In this study, we investigated the pathogenesis of these malformations by expressing Pik3ca H1047R in the CPM. Mice expressing Pik3ca H1047R in the CPM developed vascular abnormalities restricted to the head and neck. Single-cell RNA sequencing revealed that Pik3ca H1047R upregulates Vegf-a expression in endothelial cells through HIF-mediated hypoxia signaling. Human samples supported these findings, showing elevated HIF-1α and VEGF-A in malformed vessels. Notably, inhibition of HIF-1α and VEGF-A in the mouse model significantly reduced abnormal vasculature. These results highlight the role of embryonic origins and hypoxia-driven mechanisms in vascular malformations, providing a foundation for the development of therapies targeting these difficult-to-treat conditions.
Year:
2025
Year:
2025
Year:
2025
Extracranial arteriovenous malformations (AVMs) are rare aggressive vascular malformations, and half of AVMs harbor mutations in the RAS/RAF/MAPK pathway. AVMs consist of abnormal networks of small vessels formed between arteries and veins. Although the abnormal small-vessel networks are considered to cause AVM progression, the underlying mechanisms remain poorly understood. This study elucidated the mechanisms underlying the pathogenesis of extracranial AVM in relation to genetic mutations. This retrospective clinical, pathological, and genetic study included 30 patients with extracranial AVMs. MAP2K1 , KRAS , and BRAF mutations were identified in 14 (46.7%), 1 (3.3%), and 1 (3.3%) patient(s), respectively. Mutant AVMs were predominant in females, and histologically showed more infantile hemangioma-like small vessels and more enlarged small vessels inside the perineurium. Immunohistochemistry revealed high expression levels of phosphorylated ERK (extracellular signal regulated kinases), a downstream effector of the RAS/RAF/MAPK pathway, in AVMs regardless of mutational status or vessel type. Spatial transcriptomics revealed upregulation of genes involved in “positive regulation of cell adhesion”, “positive regulation of cell migration” and “blood vessel development” in the abnormal small vessels in MAP2K1 -mutant AVMs. Among the up-regulated genes, MAP4K4, which regulates pathological angiogenesis and is a therapeutic target, was highly expressed in abnormal small vessels in AVMs. This study reports significant genotype–phenotype correlations in AVMs, indicating gene-specific effects. A detailed analysis of gene-specific effects, focusing especially on abnormal small-vessel networks, may offer insights into the mechanisms underlying AVM pathogenesis and its implications for targeted therapies.
Year:
2025
Year:
2025
BACKGROUND Acute myocarditis is an immune-mediated inflammatory disease characterized by myocardial inflammation and edema. Cardiac lymphatic vessels are essential for fluid clearance and immune regulation; however, their role in modulating inflammation in autoimmune myocarditis remains largely unclear. METHODS We investigated the impact of cardiac lymphangiogenesis using a murine model of experimental autoimmune myocarditis induced by cardiac myosin peptide immunization. Human autopsy samples were analyzed for lymphatic expansion. Mice were treated with VEGF-C C156S, a VEGFR3-specific agonist, beginning one week after immunization. Cardiac lymphangiogenesis, myocardial edema, inflammatory infiltration, fibrosis, and cardiac function were evaluated by immunohistochemistry, echocardiography, gene expression analysis, and water content measurements. RESULTS The VEGF-C treatment accelerated cardiac lymphangiogenesis, enhanced lymphatic drainage, reduced myocardial edema, and attenuated inflammatory cell infiltration and fibrosis. Echocardiography showed the preservation of left ventricular function. VEGF-C selectively decreased the accumulation of iNOS⁺ inflammatory macrophages without broadly suppressing T cells or reparative macrophages. Bulk RNA sequencing confirmed the down-regulation of inflammatory gene signatures associated with macrophage activation. CONCLUSIONS The early stimulation of cardiac lymphangiogenesis by VEGF-C promotes the resolution of inflammation, reduces myocardial injury, and preserves cardiac function in autoimmune myocarditis. Targeting the cardiac lymphatic system may represent a promising therapeutic strategy for acute myocarditis.
Year:
2025
Translating genomic discoveries into therapies for rare genetic disorders remains a significant challenge, particularly for variants of unknown significance (VUS) where molecular mechanisms are unclear. This is particularly relevant in vascular malformations, where venous differentiation remains poorly understood, and the role of transcription factors in specifying venous identity is only beginning to be elucidated. Here, we combine live-cell single-molecule imaging with genomics-based approaches to uncover a biophysical mechanism of transcription factor antagonism that underpins venous identity. We show that SOX18 and NR2F2 antagonistically co-regulate venous differentiation through dynamic feedback between their nuclear populations. This interaction is disrupted in vascular malformation syndrome caused by a de novo heterozygous NR2F2 mutation, presenting with aberrant vascular integrity and bleeding. Treatment with an FDA-approved drug—known to inhibit SOX18—led to marked clinical improvement in the proband. To dissect the molecular mechanism underlying this mutation and the drug response, we used human embryonic stem cells (hESCs) engineered to carry the proband’s NR2F2 variant. These cells exhibited impaired hESC to venous differentiation with no effect on artery EC differentiation. In silico modelling and live-cell molecular imaging revealed that the NR2F2 variant is hyper-mobile, fails to form homodimers, and cannot recruit SOX18, thereby disrupting a critical transcriptional antagonism that underpins venous endothelial identity. We demonstrate that targeted pharmacological inhibition of SOX18 restores this regulatory balance in hESC-derived venous endothelial cells, rescuing both gene expression and NR2F2 binding dynamics at the single-molecule level. Together, this study uncovers a biophysical mechanism of transcription factor antagonism that governs venous differentiation and offers a framework for developing targeted therapies for rare vascular malformations.
Year:
2025
Sirt3 is a mitochondrial protein deacetylase functioning in energy metabolism, regulation of intracellular reactive oxygen species (ROS) levels, and aging. Although Sirt3 loss has negative effects on fertility of oocytes during in vitro fertilization and on progesterone production in granulosa cells, Sirt3's function in Leydig cells remains unclear. Therefore, we investigated Sirt3 activity in Leydig cells, focusing on androgen production. To do so, we performed immunohistochemistry to confirm Sirt3 localization in gonads and observed strong Sirt3 immunostaining in Leydig cells of human testes and of Sirt3+/+ and Sirt3+/− mouse testes, while Sirt3−/− mouse testis tissue was negative. In human ovary, hilus cells were strongly Sirt3-positive, theca cells showed weak positivity, and granulosa cells showed very weak or almost no immunostaining. Next, we used the murine Leydig tumor cell line MA-10 as a model. We overexpressed Sirt3 but observed no changes in proliferation, expression of Star, Cyp11a1 (p450scc gene), and Hsd3b, or progesterone production in MA-10 cells. Sirt3 knockdown significantly reduced proliferation, suppressed expressions of steroidogenic enzymes and of transcription factors Ad4bp (Sf-1 gene) and Gata4, and decreased progesterone production. Sirt3 knockdown in MA-10 cells also increased intracellular ROS levels based on CM-H2DCFDA fluorescence dye analysis and increased the proportion of both early and late apoptotic (necrotic) cells based on Annexin V/7AAD assays. These results indicate that Sirt3 has a potential function in androgen production in Leydig cells by regulating intracellular ROS levels.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Collaborators (15)
Tadashi Yamamuro
Independent Laboratory Head
National Cerebral and Cardiovascular Center
Elizabeth Hinde
University of Melbourne
Mathias Francois
Lab Head
University of Sydney
Kazuko Tajiri
Associate Professor
University of Tsukuba
Kaoru Dohi
Mie University Graduate School of Medicine
Kyoko Imanaka‐Yoshida
-
Chifumi Fujii
Shinshu University
Yuichi Tamura
International University of Health and Welfare Mita Hospital
Taku Omori
Mie university
Keiki Nagaharu
Lund University
Kristy Red-Horse
Associate Professor
Stanford University
Hiroshi Imai
Mie university
Jennifer Gamble
Wenkart Chair of the Endothelium
University of Sydney
Masatoshi Watanabe
Prof
Mie University Graduate School of Medicine
Eiichi Morii
Professor
Osaka University
Make your next move.
Prepare your application
Review drafts before you send them.